Compare NTRA & FAST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | FAST |
|---|---|---|
| Founded | 2003 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7B | 58.2B |
| IPO Year | 2015 | 1995 |
| Metric | NTRA | FAST |
|---|---|---|
| Price | $378.07 | $52.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 23 | 18 |
| Target Price | ★ $416.39 | $51.07 |
| AVG Volume (30 Days) | 1.4M | ★ 7.8M |
| Earning Date | 11-05-2026 | 10-14-2026 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | ★ 0.65 | N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | $210,939,000.00 | ★ $8,200,500,000.00 |
| Revenue This Year | $26.22 | $13.69 |
| Revenue Next Year | $20.96 | $9.47 |
| P/E Ratio | ★ N/A | $53.11 |
| Revenue Growth | N/A | ★ 8.67 |
| 52 Week Low | $181.00 | $38.97 |
| 52 Week High | $437.41 | $53.30 |
| Indicator | NTRA | FAST |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 58.00 |
| Support Level | $187.64 | $43.60 |
| Resistance Level | $437.41 | N/A |
| Average True Range (ATR) | 19.55 | 1.51 |
| MACD | -2.75 | 0.03 |
| Stochastic Oscillator | 5.74 | 86.84 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Fastenal began as an industrial retailer, expanding its product portfolio from nuts and bolts to cutting tools, safety equipment, and janitorial supplies. It transitioned into a distributor by building out a dense network of branches close to its business customers. Once a customer becomes large enough, Fastenal installs vending machines and its own personnel on-site. Today, these on-site locations exceed Fastenal's branch count and remain the firm's main focus for expansion. Fastenal acts as a one-stop outsourcing partner for its industrial customers, offering value-added services along with a wide breadth of maintenance, repair, and operations supplies.